Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. 1.3 ...
Results demonstrated that CaroSpir, the first and only FDA approved spironolactone oral suspension, delivered a consistent potency of spironolactone dose to dose, compared to compounded preparations that routinely showed potency inconsistencies. Get More Information About CaroSpir® ...
Spironolactone, a synthetic 17-lactone steroid, is a potassium-sparing diuretic that also displays antagonistic effects on the androgen and progesterone receptors.It is approved by the US Food and Drug Administration (FDA) for the treatment of heart failure, edema and ascites, hypertension, and prim...
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g. on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. ...
FDA approved six-membered ring fused pyrimidine-based derivatives SahilArora,RajKumar, inFused Pyrimidine-Based Drug Discovery, 2023 8.6Triamterene Triamterene(2,4,7-triamino-6-phenylpteridine) (8.1.51), is a potassium-sparingdiuretic drugused since 1964 (Rice, 2014) and shows the same effect as...
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. ...
2019年6月27日FDA发布《心衰药物开发指南草案》指出,当前,FDA在批准一个心衰新药时,都会要求申请人提交这个药物在致死性方面的评估结果。但FDA指出,尽管改善生存结局对于一个心衰药物意义重大,但并不要求申请人必须证明一个药物在改善心衰患者生存方面的益处,而是希望申请人有足够多的证据能够确保药物不会增加死亡风险。